Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma 2Leukemia 2Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell 1Leukemia, Lymphoid 1Burkitt Lymphoma 1

Interventions

fludarabine phosphate 3Cyclophosphamide 3pegylated granulocyte colony-stimulating factor 1ibrutinib 1forodesine 1fludarabine 1blinatumomab 1Whole-Body Irradiation 1Tacrolimus 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1Mesna 1Leukapheresis 1Immunotherapy, Adoptive 1Everolimus 1Bone Marrow Transplantation 1Biopsy 1Alemtuzumab 1ARQ531 12-(2-oxo-2-((3,7,11-trimethyl-2,6,10-dodecatrienyl)oxy)aminoethyl)phosphonic acid, (2,2-dimethyl-1-oxopropoxy)methyl ester sodium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia, Lymphoid × forodesine × Clear all
NCT00035022 2006-01-13

Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas

BioCryst Pharmaceuticals

Phase 1/2 Completed
71 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphoid, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡